Spyridon Karageorgos

Also affiliated with Queen Mary University of London, European University Cyprus, Children's Hospital Agia Sophia

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Enhancing Neuroblastoma Immunotherapies by Engaging iNKT and NK Cells”.

Enhancing Neuroblastoma Immunotherapies by Engaging iNKT and NK Cells

Frontiers in Immunology(2020)10.3389/fimmu.2020.00873

N/A

0DataRank · unranked

34 citations

Spyridon Karageorgos, Michael D. Hogarty, Hamid Bassiri, Kevin O. McNerney

Anti-GD2 antibody therapy alters the neuroblastoma tumor microenvironment and extends survival in TH-MYCN mice

bioRxiv (Cold Spring Harbor Laboratory)(2021)10.1101/2021.06.09.447746

N/A

0DataRank · unranked

1 citations

Spyridon Karageorgos, George D. Ferry, Adam J. Wolpaw, Chakkapong Burudpakdee, Priya Khurana +5 more

TH-MYCN tumors, but not tumor-derived cell lines, are adrenergic lineage, GD2+, and responsive to anti-GD2 antibody therapy

OncoImmunology(2022)10.1080/2162402x.2022.2075204

N/A

0DataRank · unranked

22 citations

Spyridon Karageorgos, GM Ferry, AJ Wolpaw, Chakkapong Burudpakdee, Priya Khurana +6 more